In Brief: CDER reorganization
This article was originally published in The Tan Sheet
Executive Summary
CDER reorganization: ODE 5 Director Michael Weintraub will also serve as acting director of FDA Center for Drug Evaluation and Research's new Division of Anti-Inflammatory, Analgesic and Dental Drug Products. Jonathan Wilkin, head of what used to be CDER's Division of Topical Drug Products, becomes director of the Division of Dermatologic and Ophthalmologic Drug Products. FDA previously announced that Debra Bowen, Medical Review Staff director, is acting director of the new Division of OTC Drug Products ("The Tan Sheet" Sept. 18, p. 1). The agency is looking for a replacement for former OTC Medical Officer Man Fung, who left in September. ODE 5 is moving to 9201 Corporate Blvd. in Rockville, Md. before the end of the year...